A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Our Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Precision medicine emerged as an approach for disease treatment as the understanding of the link between genetic alterations, protein dysfunction and diseases evolved. Precision medicine aims to specifically and potently drug genetically validated target proteins (i.e., genetic variants potentially implicated in biology of disease). However, some target proteins thus far have been intractable or inadequately addressed using conventional drug discovery tools.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -276M | -276M | -338M | -342M | -291M | -364M |
| EPS | $-1.61 | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| Free Cash Flow | -236M | -236M | -251M | -304M | -239M | -78M |
| ROIC | -49.5% | -41.1% | -43.4% | -45.5% | -30.6% | -40.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.10 | 0.12 | 0.12 | 0.06 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -303M | -303M | -372M | -373M | -299M | -365M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -48.8% | -41.1% | -43.4% | -45.5% | -30.6% | -40.5% |
| Shares Outstanding | 172M | 172M | 143M | 123M | 112M | 95M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 100M | 173M | 246M | 330M | 319M | 261M | 261M |
| SG&A | 39M | 57M | 66M | 75M | 77M | 57M | 57M |
| EBIT | -56M | -365M | -299M | -373M | -372M | -303M | -303M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -230M | -364M | -291M | -342M | -338M | -276M | -276M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 2.3M | 2.3M |
| Returns on Capital | |||||||
| ROIC | -7.0% | -40.5% | -30.6% | -45.5% | -43.4% | -41.1% | -49.5% |
| ROE | N/A | -40.5% | -30.6% | -45.5% | -43.4% | -41.1% | -48.8% |
| ROA | -28.8% | -36.1% | -26.4% | -40.5% | -38.8% | -37.0% | -44.5% |
| Cash Flow | |||||||
| Op. Cash Flow | -102M | -74M | -229M | -300M | -249M | -235M | -235M |
| Free Cash Flow | -104M | -78M | -239M | -304M | -251M | -236M | -236M |
| Owner Earnings | -138M | -127M | -290M | -392M | -349M | -301M | -301M |
| CapEx | 1.9M | 3.5M | 9.1M | 4.1M | 2.0M | 410K | 410K |
| Maint. CapEx | 3.5M | 3.9M | 4.1M | 5.3M | 5.5M | 3.6M | 3.6M |
| Growth CapEx | 0 | 0 | 4.9M | 0 | 0 | 0 | 0 |
| D&A | 3.5M | 3.9M | 4.1M | 5.3M | 5.5M | 3.6M | 3.6M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 32M | 48M | 56M | 86M | 94M | 62M | 62M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | -537M | -941M | N/A | N/A | N/A | -84M |
| Cash & Equiv. | 448M | 280M | 152M | 144M | 124M | 84M | 84M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.03 | 0.06 | 0.12 | 0.12 | 0.10 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | 898M | 950M | 752M | 778M | 567M | 567M |
| Total Assets | 800M | 1.0B | 1.1B | 844M | 871M | 621M | 621M |
| Total Liabilities | N/A | 111M | 150M | 92M | 94M | 54M | 54M |
| Intangibles | N/A | 2.3M | 2.3M | 2.3M | 2.3M | 0 | 0 |
| Retained Earnings | -404M | -768M | -1.1B | -1.4B | -1.7B | -2.0B | -2.0B |
| Working Capital | 756M | 952M | 956M | 740M | 758M | 553M | 553M |
| Current Assets | 770M | 976M | 1.0B | 770M | 809M | 578M | 578M |
| Current Liabilities | 14M | 24M | 64M | 30M | 51M | 26M | 26M |
| Per Share Data | |||||||
| EPS | -5.40 | -3.82 | -2.59 | -2.79 | -2.36 | -1.61 | -1.61 |
| Owner EPS | -1.27 | -1.33 | -2.58 | -3.20 | -2.44 | -1.76 | -1.76 |
| Book Value | N/A | 9.43 | 8.47 | 6.14 | 5.44 | 3.30 | 3.30 |
| Cash Flow/Share | -0.95 | -0.78 | -2.05 | -2.45 | -1.74 | -1.37 | -1.59 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 108.3M | 95.3M | 112.2M | 122.6M | 143.1M | 171.7M | 171.7M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -9.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.3 | 1.7 | 1.8 | 0.8 | 2.6 | 4.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -2.1% | -2.6% | -15.0% | -21.9% | -40.3% | -16.0% | -9.3% |
| Market Cap | 4.9B | 3.0B | 1.6B | 1.4B | 624M | 1.5B | 2.5B |
| Avg. Price | 41.95 | 35.50 | 21.89 | 12.40 | 7.39 | 4.43 | 14.75 |
| Year-End Price | 45.09 | 31.16 | 14.16 | 11.33 | 4.36 | 8.56 | 14.75 |
Relay Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Relay Therapeutics, Inc. (RLAY) has a 5-year average return on invested capital (ROIC) of -40.2%. This is below average and may indicate limited pricing power.
Relay Therapeutics, Inc. (RLAY) has a market capitalization of $2.5B. It is classified as a mid-cap stock.
Relay Therapeutics, Inc. (RLAY) does not currently pay a regular dividend.
Relay Therapeutics, Inc. (RLAY) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Relay Therapeutics, Inc. (RLAY) generated $-236 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Relay Therapeutics, Inc. (RLAY) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
Relay Therapeutics, Inc. (RLAY) reported earnings per share (EPS) of $-1.61 in its most recent fiscal year.
Relay Therapeutics, Inc. (RLAY) has a return on equity (ROE) of -41.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Relay Therapeutics, Inc. (RLAY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Relay Therapeutics, Inc. (RLAY) has a book value per share of $3.30, based on its most recent annual SEC filing.